β-Lactamases and β-Lactamase Inhibitors in the 21st Century.
Tooke CL, Hinchliffe P, Bragginton EC, Colenso CK, Hirvonen VHA, Takebayashi Y, Spencer J. · 2019
Read β-Lactamases and β-Lactamase Inhibitors in the 21st Century. by Tooke CL, Hinchliffe P, Bragginton EC, Colenso CK, Hirvonen VHA, Takebayashi Y, Spencer J. (2019) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6723624.txt.
Introduction
Tooke and co-authors review beta-lactamase enzymes and the drugs that block them. Beta-lactam antibiotics hold a central place in fighting bacteria. Many bacteria resist them by making enzymes that split the drug's key ring. These enzymes spread on mobile DNA between species such as E. coli and Pseudomonas.
The enzymes fall into four classes. Three use a serine site, and one uses zinc. New crystal structures and computer simulations have clarified how each class breaks drugs down. The review gives special weight to carbapenems, the last-line drugs now under threat. It also surveys new inhibitor pairings entering clinical use.
Catalog record
| CREATOR | Tooke CL, Hinchliffe P, Bragginton EC, Colenso CK, Hirvonen VHA, Takebayashi Y, Spencer J. |
|---|---|
| YEAR | 2019 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 141 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
β-Lactamases and β-Lactamase Inhibitors in the 21st Century By Catherine L Tooke, Philip Hinchliffe, Eilis C Bragginton, Charlotte K Colenso, Viivi HA Hirvonen, Yuiko Takebayashi, James Spencer Published in: Journal of Molecular Biology DOI: 10.1016/j.jmb.2019.04.002 ABSTRACT Abstract The β-lactams retain a central place in the antibacterial armamentarium. In Gram-negative bacteria, β-lactamase enzymes that hydrolyze the amide bond of the four-membered β-lactam ring are the primary resistance mechanism, with multiple enzymes disseminating on mobile genetic elements across opportunistic pathogens such as Enterobacteriaceae (e.g., Escherichia coli) and non-fermenting organisms (e.g., Pseudomonas aeruginosa). β-Lactamases divide into four classes; the active-site serine β-lactamases (classes A, C and D) and the zinc-dependent or metallo-β-lactamases (MBLs; class B). Here we review recent advances in mechanistic understanding of each class, focusing upon how growing numbers of crystal structures, in particular for β-lactam complexes, and methods such as neutron diffraction and molecular simulations, have improved understanding of the biochemistry of β-lactam breakdown. A second focus is β-lactamase interactions with carbapenems, as carbapenem-resistant bacteria are of grave clinical concern and carbapenem-hydrolyzing enzymes such as KPC (class A) NDM (class B) and OXA-48 (class D) are proliferating worldwide. An overview is provided of the changing landscape of β-lactamase inhibitors, exemplified by the introduction to the clinic of combinations of β-lactams with diazabicyclooctanone and cyclic boronate serine β-lactamase inhibitors, and of progress and strategies toward clinically useful MBL inhibitors. Despite the long history of β-lactamase research, we contend that issues including continuing unresolved questions around mechanism; opportunities afforded by new technologies such as serial femtosecond crystallography; the need for new inhibitors, particularly for MBLs; the likely impact of new β-lactam:inhibitor combinations and the continuing clinical importance of β-lactams mean that this remains a rewarding research area. Abbreviations: CTX-M, cefotaximase; DBO, diazabicyclooctane; ESBL, extended spectrum β-lactamase; KPC, Klebsiella pneumoniae carbapenemase; MBL, metallo-β-lactamase; NDM, New Delhi metallo-β-lactamase; OXA, oxacillinase; PBP, penicillin-binding protein; QM/MM, quantum mechanics/molecular mechanics; SBL, serine β-lactamase; SFX, serial femtosecond crystallography; SHV, sulfydryl variant; TEM, Temoneira (β-lactamase); VIM, Verona imipenemase Keywords: β-lactam, antimicrobial resistance, carbapenemase, enzyme mechanism, metallo-β-lactamase INTRODUCTION β-Lactam antibiotics The discovery of penicillin in 1929 [1] is rightly recognized as a milestone in the history of medicine, and its introduction to the clinic in the 1940s revolutionized our ability to treat bacterial infections. Despite enormous progress in the field of antimicrobial chemotherapy in the more than 70 years after the first use of penicillin, as the centenary of Fleming's work approaches, the β-lactams remain the cornerstones of the antibacterial arsenal. The fact that they remain both the single most prescribed antibiotic class and the most important in terms of sales [2] attests to their continuing central role in the treatment of bacterial infections. β-Lactams, like other antimicrobial classes, have undergone continuous development since their original introduction in order to improve properties such as potency, spectrum of activity, pharmacokinetic and safety profiles and to counter the emergence of resistance [3]. At present, four main classes of β-lactam antimicrobials are in clinical use (Fig. 1). These comprise three types of bicyclic structure: the penicillins (1), in which the four-membered β-lactam ring is fused to a thiazolidine ring; the cephalosporins (2), where the fusion partner is a six-membered dihydrothiazine; and the carbapenems (3), where the bicyclic system is completed by a five-membered pyrroline. A fourth class, the monobactams (6) are monocyclic systems. While each class was originally identified as a natural product (penicillin in 1929, cephalosporins by Newton and Abraham [5] (building on the work of Brotzu [4]) in 1954, olivanic acid (carbapenem) by Brown and co-workers [6] in 1976 and monobactams by Sykes and Imada and their respective co-workers [7], [8] in 1981], each has since undergone extensive programs of modification to create arrays of semi-synthetic derivatives. [Figure: Structures of representative β-lactams and β-lactamase inhibitors. 1. Penicillin scaffold. 2. Cephalosporin scaffold. 3. (1-methyl) Carbapenem scaffold. 4. Hydrolyzed carbapenem (Δ2-pyrroline form). 5. Hydrolyzed carbapenem (Δ1-pyrroline form). 6. Monobactam scaffold. 7. Clavulanic acid. 8. Avibactam. 9. Relebactam. 10. Vaborbactam. 11. Bicyclic boronate.] The antibacterial activity of β-lactams was identified by Tipper and Strominger [9] as based on their resemblance to the terminal d-Ala–d-Ala moiety of the peptidoglycan stem pentapeptide, with the β-lactam amide and adjoining carboxylate (or, in the case of monobactams, sulfonic acid) groups serving to mimic the peptide bond and terminal carboxylate of d-Ala–d-Ala. Activity then arises from reaction of the β-lactam ring with the nucleophilic serine of target penicillin-binding proteins (PBPs), leading to opening of the ring and irreversible PBP acylation [10] that prevents formation of peptidoglycan transpeptide cross-links. In consequence, modification that allows for retention of antibacterial activity is possible at several positions on the β-lactam scaffold: C6 of penicillins, C7 and C3 of cephalosporins, C2 of carbapenems and C3 of monobactams. Key developments arising from such modifications include introduction of aminopenicillins (e.g., ampicillin) that extended antibacterial activity of penicillins to include Gram-negative bacteria [11]; introduction of methicillin to counter penicillin-resistant strains of Staphylococcus aureus [12]; and introduction of oxyiminocephalosporins [13] (e.g., cefotaxime, ceftazidime) to counter emergence of β-lactamase-mediated resistance in Gram-negative bacteria. β-Lactamase mediated β-lactam resistance As with other antimicrobial classes, extensive use of β-lactams has led to the emergence and dissemination of resistance. Resistance can occur by multiple mechanisms, including modification of the target (mutation or expression of alternative PBPs), reduction in cell permeability through downregulation of porins required for β-lactam entry, over-expression of efflux systems and production of modifying or degradative enzymes [14]. In the case of β-lactams, enzyme-mediated resistance arises from the activity of β-lactamases, enzymes produced by both Gram-positive and Gram-negative bacteria that hydrolyze the β-lactam amide [15]. It is not always appreciated that enzymes able to degrade penicillin were identified in Escherichia coli even before its first use in man [16], although as initial penicillin use focused largely on infections by Gram-positive pathogens, the significance of this finding was not immediately apparent. β-Lactamases, however, quickly became clinically important as resistance in S. aureus arising from production of the PC1 enzyme [17] (encoded by the blaZ gene) rapidly compromised penicillin effectiveness. This and the successful countering of PC1-producing organisms through introduction of methicillin [12] heralded the beginning of an “arms race” between medicinal chemists and bacterial evolution that continues to this day and that has seen the introduction of new β-lactams lead to emergence of new β-lactamases both by mutation of previously known families and dissemination of genes encoding new enzymes. Despite the initial importance of PC1-mediated penicillin resistance in S. aureus, in Gram-positive bacteria, the emergence of strains carrying PBP alterations has largely superseded β-lactamase production as the primary mechanism of β-lactam resistance [18]. In consequence, this review will largely focus on Gram-negative bacteria, where β-lactamases remain the primary β-lactam resistance mechanism, although it is important to note that in the clinic resistance is very often multifactorial and phenotype is driven by combinations of mechanisms that frequently include permeability modifications and/or efflux pump upregulation in addition to β-lactamase production. A further complication is the increasing prevalence of strains expressing multiple β-lactamases, often encoded upon single multiresistance plasmids (for recent reviews, see Refs. [19], [20]). Classification of β-lactamases Identification of growing numbers of β-lactamases, coupled with availability of protein, and subsequently nucleotide, sequence information, established that these enzymes do not comprise a single homogeneous